Literature DB >> 19416163

Activation of relaxin-related receptors by short, linear peptides derived from a collagen-containing precursor.

Ronen Shemesh1, Chen Hermesh, Amir Toporik, Zurit Levine, Amit Novik, Assaf Wool, Yossef Kliger, Avi Rosenberg, Ross A D Bathgate, Yossi Cohen.   

Abstract

In a screening effort based on algorithmic predictions for novel G-protein-coupled receptor (GPCR) peptide activators, we were able to identify and examine two novel peptides (P59 and P74) which are short, linear, and derived from a natural, previously unidentified precursor protein containing a collagen-like repeat. Both peptides seemed to show an apparent cAMP-related effect on CHO-K1 cells transiently transfected with either LGR7 or LGR8, usually after treatment with cAMP-generating forskolin, compared to the same cells treated with forskolin plus relaxin. This activation was not found for the relaxin-3 receptor (GPR135). In a set of follow-up experiments, both peptides were found to stimulate cAMP production, mostly upon initial stimulation of cAMP production by 5 micro M forskolin in cells transfected with either LGR7 or LGR8. In a dye-free cell impedance GPCR activation assay, we were able to show that these peptides were also able to activate a cellular response mediated by these receptors. Although untransfected CHO-K1 cells showed some cellular activation by both relaxin and at least one of our newly discovered peptides, both LGR7- and LGR8-transfected cells showed a stronger response, indicating stimulation of a cellular pathway through activation of these receptors. In conclusion, we were able to show that these newly discovered peptides, which have no similarity to any member of the relaxin-insulin-like peptide family, are potential ligands for the relaxin-related family of receptors and as such might serve as novel candidates for relaxin-related therapeutic indications. Both peptides are linear and were found to be active after being chemically synthesized.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19416163     DOI: 10.1111/j.1749-6632.2009.03827.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  6 in total

Review 1.  Synthetic non-peptide low molecular weight agonists of the relaxin receptor 1.

Authors:  Alexander I Agoulnik; Irina U Agoulnik; Xin Hu; Juan Marugan
Journal:  Br J Pharmacol       Date:  2016-11-30       Impact factor: 8.739

Review 2.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

Review 3.  Structural commonality of C1q TNF-related proteins and their potential to activate relaxin/insulin-like family peptide receptor 1 signalling pathways in cancer cells.

Authors:  Thomas Klonisch; Aleksandra Glogowska; Thatchawan Thanasupawat; Maxwell Burg; Jerry Krcek; Marshall Pitz; Appalaraju Jaggupilli; Prashen Chelikani; G William Wong; Sabine Hombach-Klonisch
Journal:  Br J Pharmacol       Date:  2016-08-11       Impact factor: 8.739

4.  Identification and optimization of small-molecule agonists of the human relaxin hormone receptor RXFP1.

Authors:  Jingbo Xiao; Zaohua Huang; Catherine Z Chen; Irina U Agoulnik; Noel Southall; Xin Hu; Raisa E Jones; Marc Ferrer; Wei Zheng; Alexander I Agoulnik; Juan J Marugan
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

5.  Synthetic short-chain peptide analogues of H1 relaxin lack affinity for the RXFP1 receptor and relaxin-like bioactivity. Clues to a better understanding of relaxin agonist design.

Authors:  Annunziata D'Ercole; Silvia Nistri; Lorenzo Pacini; Alfonso Carotenuto; Federica Santoro; Anna Maria Papini; Ross A D Bathgate; Daniele Bani; Paolo Rovero
Journal:  Front Pharmacol       Date:  2022-08-11       Impact factor: 5.988

Review 6.  RXFP1 is Targeted by Complement C1q Tumor Necrosis Factor-Related Factor 8 in Brain Cancer.

Authors:  Thatchawan Thanasupawat; Aleksandra Glogowska; Maxwell Burg; G William Wong; Cuong Hoang-Vu; Sabine Hombach-Klonisch; Thomas Klonisch
Journal:  Front Endocrinol (Lausanne)       Date:  2015-08-13       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.